Continued Innovation – Holotype HLA V2.2

30/11/2017

Omixon is delighted to announce the latest evolution of our world-leading HLA Typing product – Holotype HLA V2.1 and V2.2. Both versions deliver improved amplification robustness, increased allele coverage across Class II loci and decreased the library preparation turnaround time to ~4.3h. The major difference between V2.1 and V2.2...

Celebrate Our Corporate Growth!

29/11/2017

Since being founded as a software company in 2011, Omixon has evolved in numerous ways, including a pivot in 2014 to become a burgeoning global molecular diagnostics company with expertise in HLA, immunogenetics, software development, bioinformatics & genomics across all divisions in the company. As we push on towards...

Lab “Train Me” Video: How to Set Up the Holotype HLA Lab

07/11/2017

Welcome to our latest lab Train Me video! This time Efi Melista, Omixon’s Head of Field and Lab Operations will be describing how the workflow works and how you can set up your own Holotype HLA lab efficiently. To check all our previous Train Me videos, please visit the...

ASH, December 9-12, 2017

01/11/2017

2017 American Society of Hematology Annual Meeting and Exposition will be held in Atlanta, Georgia in December. Register and read more here…

Omixon and World Fusion Extend Their Partnership in Japan

27/10/2017

World Fusion is a leading bioinformatics company in Japan that focuses on therapeutic target discovery, gene expression analysis, and variant analysis. Their highly skilled and motivated team has been the successful marketer of Omixon’s software products since 2014, and we are pleased to announce World Fusion as a distributor...